

## **Medicortex continues research with the US Department of Defense**

**Medicortex Finland Plc, a biotechnology company based in Turku, Finland, announces continued development of saliva test for early detection of Traumatic Brain Injury (TBI) in the ongoing program with the U.S. Army Medical Research and Development Command (USAMRDC).**

The granted extension will continue the project which commenced in 2024 by one year, with the extended project period now running through June 2027. The continuation enables further development of the saliva based TBI test and strengthening its performance for rapid and accurate detection of TBI in decentralized field-testing conditions. The total funding for this project, awarded by the Department of Defense (DoD) in June 2024, amounts to approximately USD 1.4 million and covers the full project period from June 2024 through June 2027. No additional funding has been awarded in connection with this extension.

“This is great news and I see it underlining the DoD’s confidence in Medicortex’s capacity to develop innovative solutions to tackle medical issues frequently encountered in the military activity”, says Dr. Adrian Harel, the CEO and founder of Medicortex. “Together with the forthcoming corporate arrangement this will allow us to continue our activity to translate research results into clinical utility on a stronger base”, Dr. Harel concludes.

The structural arrangement mentioned by the CEO refers to the intended business transaction between the Swedish company Nosium AB (publ) and Medicortex whereby Nosium is acquiring the majority of shares in Medicortex from company’s shareholders via a share swap. After completion of the planned transaction the shares will be publicly traded at Nordic Growth Market NGM in Stockholm and the company will get better access to the international financial markets.

### **Forward-looking statements**

Certain statements in this communication are forward-looking statements. They are based on the views of the company’s management, as well as the understanding and assumptions of the company’s management based on the information available at present, and due to this, they may be forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors, which may result in that the company’s actual future results, operations, achievements and performance of the sector may differ significantly from the expectations conveyed in these statements. Forward-looking statements are not a guarantee of the company’s operational or financial performance in the future.

### **Contacts**

Adrian Harel, CEO  
Tel: +358 400 488 817  
Email: [adrian.harel@medicortex.fi](mailto:adrian.harel@medicortex.fi)

### **About the company**

Medicortex Finland Oyj is a biotechnology company dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI). Its current focus is on developing biomarker diagnostics to detect brain injury easily. The company has technology to capture biomarkers from urine and saliva and capability to develop an affordable diagnostic tool to detect biomarkers. Company's second goal is to develop new compounds to serve as drug candidates to halt progression of brain injury and reduce the secondary degeneration. Medicortex was founded by an experienced Neurobiologist Adrian Harel (PhD, MBA) and the company is based in Turku, Finland.